4M Therapeutics Inc. has released promising results from completed GLP safety studies for its lead asset, 4MT-2001, supporting its potential to offer a safer treatment option to patients who are underserved by lithium and atypical antipsychotics.
4M Therapeutics Inc. has been awarded a $120,000 grant from SynGAP Research Fund (SRF) to evaluate central nervous system (CNS) effects of novel glycogen synthase kinase 3 β (GSK-3β) inhibitors 4MT-2001 and 4MT-1060.
4M Therapeutics Inc. has released new preclinical data for its lead program, 4MT-2001, a novel small-molecule glycogen synthase kinase 3β (GSK-3β) inhibitor, demonstrating central nervous system (CNS) target engagement.
4M Therapeutics Inc. has announced the presentation of preclinical data on its small-molecule glycogen synthase kinase-3β (GSK-3β) inhibitors in models of bipolar disorder.
